Cited by 317Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

Open access

La Joie, Renaud, Ayakta, Nagehan, Seeley, William W., Borys, Ewa, Boxer, Adam L., DeCarli, Charles, Doré, Vincent, Grinberg, Lea T., Huang, Eric, Hwang, Ji‐Hye, Ikonomovic, Milos D., Jack, Clifford, Jagust, William J., Jin, Lee‐Way, Klunk, William E., Kofler, Julia, Lesman‐Segev, Orit H., Lockhart, Samuel N., Lowe, Val J., Masters, Colin L., Mathis, Chester A., McLean, Catriona L., Miller, Bruce L., Mungas, Daniel, O'Neil, James P., Olichney, John M., Parisi, Joseph E., Petersen, Ronald C., Rosen, Howard J., Rowe, Christopher C., Spina, Salvatore, Vemuri, Prashanthi, Villemagne, Victor L., Murray, Melissa E., Rabinovici, Gil D.·2019·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2018.09.001PMC PMC6368897

Open this paper in CoChat — free account

Abstract

Introduction: We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]PIB‐PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ‐PET quantification. Methods: Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results: CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET‐pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate‐to‐frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate‐to‐high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Discussion: Our study demonstrated the robustness of a multisite Centiloid [ 11 C]PIB‐PET study and established a range of pathology‐based CL thresholds.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2018.09.001

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“In addition to these Ab centric scales, we studied AD neuropathologic change (ADNC) levels, which combine information from Ab (CERAD and Thal) and tau pathology (Braak staging [19]) into a global four-point summary scale recommended for AD neuropathologic diagnosis [20].”
Background
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Self-citation
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Self-citation
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
Self-citation
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Self-citation
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. (2017) · Nature Communications · doi:10.1038/s41467-017-01150-x · Cited by 911
Self-citation
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855

Show all 47 references

Research works printed but not linked: 1

Duque‐Castaño A, 1999, [Neuropathological findings in early‐onset Alzheimer's disease (E280a‐PS1 mutation)], Rev Neurol, 29, 1

Sorted by citations

Items 101–200 of 317

Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0837-9 · Cited by 44
Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study
Bollack, A., Collij, L. E., García, D. V., Shekari, M., Altomare, D., Payoux, P., Dubois, B., Grau‐Rivera, O., Boada, M., Marquié, M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13761 · Cited by 43
Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine
Bougea, A. M., & Gourzis, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164661 · Cited by 43
CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease
Kurihara, M., Komatsu, H., Sengoku, R., Shibukawa, M., Morimoto, S., Matsubara, T., Arakawa, A., Orita, M., Ishibashi, K., Mitsutake, A., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201647 · Cited by 40
Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease
Cai, Y. Q., Du, J., Li, A., Zhu, Y., Xu, L., Sun, K., Ma, S., Guo, T., & Initiative, A. D. N. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01178-w · Cited by 41
Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Wiste, H. J., Graff‐Radford, J., Algeciras‐Schimnich, A., Lowe, V. J., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13539 · Cited by 38
Self-citation
Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes
Meyer, S. D., Blujdea, E. R., Schaeverbeke, J. M., Reinartz, M., Luckett, E. S., Adamczuk, K., Laere, K. V., Dupont, P. J., Teunissen, C. E., Vandenberghe, R. R., et al. (2023) · Brain · doi:10.1093/brain/awad330 · Cited by 43
Software development for quantitative analysis of brain amyloid PET
Matsuda, H., & Yamao, T. (2022) · Brain and Behavior · doi:10.1002/brb3.2499 · Cited by 37
New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases
De Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
Plasma p‐tau181/Aβ 1‐42 ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ 1‐42 and future cognitive decline
Fowler, C. J., Stoops, E., Rainey‐Smith, S. R., Vanmechelen, E., Vanbrabant, J., Dewit, N., Mauroo, K., Maruff, P. T., Rowe, C. C., Fripp, J., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12375 · Cited by 36
Self-citation
An integrated view of the relationships between amyloid, tau, and inflammatory pathophysiology in Alzheimer's disease
Arnsten, A. F. T., Tredici, K. D., Barthélemy, N. R., Gabitto, M. I., van Dyck, C. H., Lein, E. S., Braak, H., & Datta, D. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70404 · Cited by 39
Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters
Coutinho, A. M., Busatto, G. F., Porto, F. H. D. G., Faria, D. D. P., Ono, C. R., Garcez, A. T., Squarzoni, P., Duran, F., de Oliveira, M. O., Trés, E. S., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04714-0 · Cited by 36
Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
Jia, L., Zhu, M., Yang, J., Pang, Y., Wang, Q., Li, Y., Li, T., Li, F., Wang, Q., Li, Y., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02142-x · Cited by 38
Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease
Josephs, K. A., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Schwarz, C. G., Senjem, M. L., Machulda, M. M., Kantarci, K., Knopman, D. S., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado8076 · Cited by 40
Self-citation
Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease
Chatterjee, P., Doré, V., Pedrini, S., Krishnadas, N., Thota, R. N., Bourgeat, P., Ikonomović, M. D., Rainey‐Smith, S. R., Burnham, S. C., Fowler, C. J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220908 · Cited by 36
Self-citation
Network anatomy in logopenic variant of primary progressive aphasia
Mandelli, M. L., Lorca‐Puls, D. L., Lukic, S., Montembeault, M., Gajardo‐Vidal, A., Licata, A. E., Scheffler, A., Battistella, G., Grasso, S. M., Bogley, R., et al. (2023) · Human Brain Mapping · doi:10.1002/hbm.26388 · Cited by 30
Self-citation
AmyloidPETNet: Classification of Amyloid Positivity in Brain PET Imaging Using End-to-End Deep Learning
Fan, S., Ponisio, M. R., Xiao, P., Ha, S. M., Chakrabarty, S., Lee, J. J., Flores, S. E., LaMontagne, P., Gordon, B. A., Raji, C. A., et al. (2024) · Radiology · doi:10.1148/radiol.231442 · Cited by 33
Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies
Joie, R. L., Cummings, J. L., Dage, J. L., Galasko, D. R., Ikonomović, M. D., Karikari, T. K., Landau, S. M., Llibre‐Guerra, J. J., Mummery, C. J., Ossenkoppele, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70997 · Cited by 35
Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
Meyer, S. D., Vanbrabant, J., Schaeverbeke, J. M., Reinartz, M., Luckett, E. S., Dupont, P. J., Laere, K. V., Stoops, E., Vanmechelen, E., Poesen, K., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51553 · Cited by 32
Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET
Meyer, S. D., Schaeverbeke, J. M., Luckett, E. S., Reinartz, M., Blujdea, E. R., Cleynen, I., Dupont, P. J., Laere, K. V., Vanbrabant, J., Stoops, E., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae162 · Cited by 29
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous
Abrahamson, E. E., Kofler, J., Becker, C. R., Price, J. C., Newell, K. L., Ghetti, B. F., Murrell, J. R., McLean, C., López, O. L., Mathis, C. A., et al. (2021) · Brain · doi:10.1093/brain/awab434 · Cited by 28
Self-citation
Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias
Tsoy, E., Joie, R. L., VandeVrede, L. A., Rojas, J. C., Yballa, C., Chan, B., Lago, A. L., Rodriguez, A., Goode, C. A., Erlhoff, S. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13686 · Cited by 28
Self-citation
Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable
Farrar, G., Weber, C. J., & Rabinovici, G. D. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100008 · Cited by 27
Self-citation
Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
Matsuda, H., Okita, K., Motoi, Y., Mizuno, T., Ikeda, M., Sanjo, N., Murakami, K., Kambe, T., Takayama, T., Yamada, K., et al. (2022) · Annals of Nuclear Medicine · doi:10.1007/s12149-022-01792-y · Cited by 29
Evaluation of plasma p‐tau217 for detecting amyloid pathology in a heterogeneous community‐based cohort
Rudolph, M. D., Sutphen, C. L., Register, T. C., Lockhart, S. N., Rundle, M. M., Hughes, T. M., Bateman, J. R., Sai, K. K. S., Whitlow, C. T., Craft, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70426 · Cited by 29
Self-citation
Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease
Chen, C. D., Joseph‐Mathurin, N., Sinha, N., Zhou, A., Li, Y., Friedrichsen, K. A., McCullough, A. A., Franklin, E. E., Hornbeck, R. C., Gordon, B. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02342-y · Cited by 27
Self-citation
Nanoscale imaging of pT217‐tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early‐stage neurodegeneration
Datta, D., Perone, I., Wijegunawardana, D., Liang, F., Morozov, Y. M., Arellano, J. I., Duque, A., Xie, Z., van Dyck, C. H., Joyce, M. K. P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13737 · Cited by 28
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
VandeVrede, L. A., Joie, R. L., Horiki, S., Mundada, N. S., KOESTLER, M. E., Hwang, J., Ljubenkov, P. A., Rojas, J. C., Rabinovici, G. D., Boxer, A. L., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02631-8 · Cited by 28
Self-citation
Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01005-5 · Cited by 25
Quantitative Brain Amyloid PET
Jagust, W. J., Mattay, V. S., Krainak, D. M., Wang, S., Weidner, L. D., Hofling, A. A., Koo, H., Hsieh, P., Kuo, P. H., Farrar, G., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265766 · Cited by 25
Self-citation
Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer’s disease in a multicenter and multiethnic aging population
Lan, G., Wang, M., González‐Ortiz, F., Zhang, L., Li, A., Li, B., Jiang, M., Yang, J., Chen, X., Shi, D., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00904-3 · Cited by 31
Operationalizing the centiloid scale for [ 18 F]florbetapir PET studies on PET/MRI
Coath, W., Marc Modat, A., Cardoso, M. J., Markiewicz, P. J., Lane, C., Parker, T. D., Keshavan, A., Buchanan, S. M., Keuss, S. E., Harris, M., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12434 · Cited by 26
Non-canonical pathways associated to Amyloid beta and tau protein dyshomeostasis in Alzheimer’s disease: A narrative review
Maggiore, A., Latina, V., D’Erme, M., Amadoro, G., & Coccurello, R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102578 · Cited by 25
Hospitalization, Alzheimer's Disease and Related Neuropathologies, and Cognitive Decline
James, B. D., Wilson, R. S., Capuano, A. W., Boyle, P. A., Shah, R. C., Lamar, M., Ely, E. W., Bennett, D. A., & Schneider, J. A. (2019) · Annals of Neurology · doi:10.1002/ana.25621 · Cited by 25
Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes
Whitwell, J. L., Tosakulwong, N., Schwarz, C. C., Senjem, M. L., Spychalla, A. J., Duffy, J. R., Graff-Radford, J., Machulda, M. M., Boeve, B. F., Knopman, D. S., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010948 · Cited by 23
Self-citation
Changes in the language system as amyloid-β accumulates
Reinartz, M., Gabel, S., Schaeverbeke, J. M., Meersmans, K., Adamczuk, K., Luckett, E. S., Meyer, S. D., Laere, K. V., Sunaert, S. G., Dupont, P. J., et al. (2021) · Brain · doi:10.1093/brain/awab335 · Cited by 26
β-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury
Hicks, A. J., Ponsford, J. L., Spitz, G., Doré, V., Krishnadas, N., ROBERTS, C. M., & Rowe, C. C. (2022) · Neurology · doi:10.1212/wnl.0000000000200857 · Cited by 26
Self-citation
Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology
Figdore, D. J., Wiste, H. J., Bornhorst, J. A., Bateman, R. J., Li, Y., Graff‐Radford, J., Knopman, D. S., Vemuri, P., Lowe, V. J., Jack, C. R., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12545 · Cited by 24
Self-citation
Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer’s disease compared to comorbid cases; proof of concept in the ADNI study
Ioannou, K., Bucci, M., Tzortzakakis, A., Savitcheva, I., Nordberg, A. K., Chiotis, K., & Initiative, A. D. N. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02672-9 · Cited by 35
Association of APOE -Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults
Xicota, L., Gyorgy, B., Grenier‐Boley, B., Lecoeur, A., Fontaine, G., Danjou, F., Samper‐Gonzàlez, J., Olivier Colliot, A., Amouyel, P., Martin, G., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200544 · Cited by 22
[18F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration
Blazhenets, G., Soleimani‐Meigooni, D. N., Thomas, W. P., Mundada, N. S., Brendel, M., Vento, S. A., VandeVrede, L. A., Heuer, H. W., Ljubenkov, P. A., Rojas, J. C., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265856 · Cited by 23
Self-citation
Plasma p‐tau217 concordance with amyloid PET among ethnically diverse older adults
Asken, B. M., DeSimone, J. C., Wang, W., McFarland, K. N., Arias, F., Levy, S.-A. T., Fiala, J. A., Vélez-Uribe, I., Mayrand, R. P., Sawada, L. O., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12617 · Cited by 23
Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration
Povala, G., Bellaver, B., Bastiani, M. A. D., Ferrari‐Souza, J. P., Aguzzoli, C. S., Leffa, D. T., Ferreira, P. C. L., Lussier, F. Z., da Rocha, A. S., Zalzale, H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70746 · Cited by 24
Self-citation
Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts
Cacciaglia, R., Salvadó, G., Molinuevo, J. L., Shekari, M., Falcón, C., Operto, G., Suárez‐Calvet, M., Milà‐Alomà, M., Sala, A., Rodriguez‐Vieitez, E., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01436-7 · Cited by 23
The clinical importance of suspected non-Alzheimer disease pathophysiology
Vos, S. J. B., Delvenne, A., Jack, C. R., Thal, D. R., & Visser, P. J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00962-y · Cited by 23
Self-citation
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease
Rosen, J., & Jessen, F. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100102 · Cited by 21
Sex differences in amyloid PET in a large, real‐world sample from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) Study
Raya, M. A., Zeltzer, E., Blazhenets, G., Schonhaut, D. R., Allen, I. E., Carrillo, M. C., Gatsonis, C. G., Hanna, L., Hillner, B. E., Iaccarino, L., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70304 · Cited by 22
Self-citation
Toward a Universal Readout for18F-Labeled Amyloid Tracers: The CAPTAINs Study
Bischof, G. N., Bartenstein, P., Barthel, H., van Berckel, B. N. M., Doré, V., van Eimeren, T., Foster, N. L., Hammes, J., Lammertsma, A. A., Minoshima, S., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.250290 · Cited by 21
Self-citation
Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging
Alves, I. L., Heeman, F., Collij, L. E., Salvadó, G., Tolboom, N., Vilor‐Tejedor, N., Markiewicz, P. J., Yaqub, M. M., Cash, D. M., Mormino, E. C., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00819-2 · Cited by 22
Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer’s disease
Lian, Y., Jia, Y., Wong, J., Zhou, X., Song, W., Guo, J., Masters, C. L., & Wang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02324-4 · Cited by 25
Self-citation
Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer
Milà‐Alomà, M., Salvadó, G., Shekari, M., Grau‐Rivera, O., Sala‐Vila, A., Sánchez‐Benavides, G., Arenaza‐Urquijo, E. M., Gónzalez‐de‐Echávarri, J. M., Simon, M., Kollmorgen, G., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.51 · Cited by 22
AMYQ: An index to standardize quantitative amyloid load across PET tracers
Pegueroles, J., Montal, V., Bejanin, A., Vilaplana, E., Aranha, M. R., Santos‐Santos, M., Alcolea, D. A., Carrió, I., Camacho, V., Blesa, R., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12317 · Cited by 21
Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study
Jack, C. R., Hu, M., Wiste, H. J., Knopman, D. S., Vemuri, P., Graff‐Radford, J., Lowe, V. J., Vassilaki, M. E., Cogswell, P. M., Schwarz, C. G., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00350-3 · Cited by 26
Self-citation
High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed-dementia cohort
Gong, K., Timsina, J., Ali, M., Chen, Y., Liu, M., Wang, C., Pottier, C. P., Feld, G. K., Heo, G., Benzinger, T. L. S., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00909-x · Cited by 26
Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease
Kac, P. R., Alcolea, D. A., Montoliu‐Gaya, L., Fernández, S., Lantero‐Rodriguez, J., Maure‐Blesa, L., González‐Ortiz, F., Benejam, B., Turton, M., Barroeta, I., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70172 · Cited by 22
The 2024 NIA-AA biological definition of Alzheimer’s disease: linking biomarkers to clinical practice
Kobayashi, G., Hirata, K., Ono, M., Kasuga, K., & Takado, Y. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1736297 · Cited by 22
Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile
Milà‐Alomà, M., Shekari, M., Salvadó, G., Gispert, J. D., Arenaza‐Urquijo, E. M., Operto, G., Falcón, C., Vilor‐Tejedor, N., Grau‐Rivera, O., Sala‐Vila, A., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00863-y · Cited by 20
Modifiable Lifestyle Activities Affect Cognition in Cognitively Healthy Middle-Aged Individuals at Risk for Late-Life Alzheimer’s Disease
Heneghan, A., Deng, F., Wells, K., Ritchie, K., Muniz-Terrera, G., Ritchie, C. W., Lawlor, B., & Naci, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220267 · Cited by 18
Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition
Drzezga, A. E., & Barthel, H. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270152 · Cited by 18
Advances in PET imaging of protein aggregates associated with neurodegenerative disease
Higuchi, M., Tagai, K., Takahata, K., & Endo, H. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01126-2 · Cited by 21
Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
Luckett, E. S., Abakkouy, Y., Reinartz, M., Adamczuk, K., Schaeverbeke, J. M., Verstockt, S., Meyer, S. D., Laere, K. V., Dupont, P. J., Cleynen, I., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01079-4 · Cited by 18
Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers
Lowe, V. J., Mester, C. T., Lundt, E. S., Lee, J., Ghatamaneni, S., Algeciras‐Schimnich, A., Campbell, M. R., Graff‐Radford, J., Nguyen, A. T., Min, H.-K. P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14317 · Cited by 20
Self-citation
Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease
Buckley, R. F. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01026-5 · Cited by 18
The Role of Amyloid- and Tau PET in the New Era of Alzheimer Disease Therapies
Chiotis, K., Wang, Y., Joie, R. L., & Rabinovici, G. D. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268339 · Cited by 18
Self-citation
Crossed cerebellar diaschisis on 18 F-FDG PET: Frequency across neurodegenerative syndromes and association with 11 C-PIB and 18 F-Flortaucipir
Provost, K., Joie, R. L., Strom, A., Iaccarino, L., Edwards, L., Mellinger, T. J., Pham, J. Q., Baker, S. L., Miller, B. L., Jagust, W. J., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211001216 · Cited by 17
Self-citation
Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of Alzheimer’s disease
Müller, E. G., Stokke, C., Stokmo, H. L., Edwin, T. H., Knapskog, A., & Revheim, M.-E. R. (2021) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-21-188 · Cited by 17
Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
Luckett, E. S., Zielonka, M., Kordjani, A., Schaeverbeke, J. M., Adamczuk, K., Meyer, S. D., Laere, K. V., Dupont, P. J., Cleynen, I., & Vandenberghe, R. R. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01242-5 · Cited by 18
AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention
Meyer, P., McSweeney, M., Gonneaud, J., & Villeneuve, S. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.001 · Cited by 20
Lower Locus Coeruleus Integrity Signals Elevated Entorhinal Tau and Clinical Progression in Asymptomatic Older Individuals
Engels, N., Riphagen, J. M., Egroo, M. V., Koops, E. A., Smegal, L. F., Becker, J. A., Prokopiou, P. C., Bueichekú, E., Kwong, K. K., Rentz, D. M., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27022 · Cited by 19
Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study
Guillén, N., Contador, J., Buongiorno, M., Álvarez, I., Cullell, N., Alcolea, D. A., Lleó, A., Fortea, J., Piñol‐Ripoll, G., Carnes, A., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01701-y · Cited by 17
APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-β
Ossenkoppele, R., & van der Flier, W. M. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4046 · Cited by 15
Concordance between Centiloid Quantification and Visual Interpretation of Amyloid PET Scans across the Alzheimer Disease Continuum
Khalafi, M., Hojjati, S. H., Wang, X. H., Zhou, L., Nordvig, A. S., Li, Y., Butler, T., Razlighi, Q. R., Tanzi, E. B., Pahlajani, S. S., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8743 · Cited by 15
Amyloid PET quantification using low-dose CT-guided anatomic standardization
Matsuda, H., Yamao, T., Shakado, M., Shigemoto, Y., Okita, K., & Sato, N. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00867-7 · Cited by 14
Quantitative comparative analysis of amyloid PET images using three radiopharmaceuticals
Jeong, Y. J., Yoon, H. J., Kang, D., & Park, K. W. (2023) · Annals of Nuclear Medicine · doi:10.1007/s12149-023-01824-1 · Cited by 14
Amyloid-PET imaging predicts functional decline in clinically normal individuals
Quenon, L., Collij, L. E., García, D. V., Alves, I. L., Gérard, T., Malotaux, V., Huyghe, L., Gispert, J. D., Jessen, F., Visser, P. J., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01494-9 · Cited by 15
Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease
Bellaver, B., Povala, G., Ferreira, P. C. L., Bauer‐Negrini, G., Lussier, F. Z., Leffa, D. T., Ferrari‐Souza, J. P., Rodrigues, M. S., Amaral, L., Oliveira, M. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70209 · Cited by 15
The Rapid Naming Test: Development and initial validation in typically aging adults
Stiver, J., Staffaroni, A. M., Walters, S. M., You, M. Y., Casaletto, K. B., Erlhoff, S. J., Possin, K. L., Lukic, S., Joie, R. L., Rabinovici, G. D., et al. (2021) · The Clinical Neuropsychologist · doi:10.1080/13854046.2021.1900399 · Cited by 14
Self-citation
Amyloid-β PET Classification on Cognitive Aging Stages Using the Centiloid Scale
de Souza, G. S., Andrade, M. A., Borelli, W. V., Schilling, L. P., Matushita, C. S., Portuguez, M. W., da Costa, J. C., & da Silva, A. M. M. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01660-7 · Cited by 16
Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation
Johns, E., Vossler, H. A., Young, C. B., Carlson, M. L., Winer, J. R., Younes, K., Park, J., Rathmann-Bloch, J. E., Smith, V., Harrison, T. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13893 · Cited by 13
Spatial extent as a sensitive amyloid‐PET metric in preclinical Alzheimer's disease
Farrell, M. E., Thibault, E. G., Becker, J. A., Price, J. C., Healy, B. C., Hanseeuw, B. J., Buckley, R. F., Jacobs, H. I. L., Schultz, A. P., Chen, C. D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14036 · Cited by 13
Use of anti-amyloid therapies for Alzheimer’s disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology
Barbosa, B. J. A. P., Resende, E. D. P. F., Castilhos, R. M., Borelli, W. V., Frota, N. A. F., Balthazar, M. L. F., Filho, A. C. S. A., Smid, J., Barbosa, M. T., Coutinho, A. M., et al. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-c002 · Cited by 17
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
Jack, C. R., Graf, A., Burnham, S. C., Doty, E. G., Moebius, H. J., Montenigro, P. H., Siemers, E., Sink, K. M., Shaw, L. M. J., Hansen, C. T., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70013 · Cited by 15
Self-citation
Staging Alzheimer’s disease through amyloid and tau PET
Johnson, D. R., Wiste, H. J., Lowe, V. J., Schwarz, C. G., Knopman, D. S., Vemuri, P., Kantarci, K., Boeve, B. F., Graff‐Radford, J., Cogswell, P. M., et al. (2025) · Brain · doi:10.1093/brain/awaf346 · Cited by 13
Self-citation
Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
Wilson, D. H., Khare, M., Triana‐Baltzer, G., Wolfe, M., Sheehy, P., Copeland, K. A. F., Hesterberg, L. K., Vasko, A.-J., van der Flier, W. M., Verberk, I. M. W., et al. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1568971 · Cited by 12
Development of software for measuring brain amyloid accumulation using 18 F‐florbetapir PET and calculating global Centiloid scale and regional Z ‐score values
Matsuda, H., Soma, T., Okita, K., Shigemoto, Y., & Sato, N. (2023) · Brain and Behavior · doi:10.1002/brb3.3092 · Cited by 11
Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer’s disease
Chen, Y., Zeng, X., Olvera‐Rojas, M., Sewell, K. R., Sehrawat, A., Gu, J. M., Triviño‐Ibáñez, E. M., Solis‐Urra, P., Gómez-Río, M., Oberlin, L. E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68372-w · Cited by 13
Self-citation
Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78–94
Michalowska, M. M., Herholz, K., Hinz, R., Amadi, C., McInnes, L., Anton-Rodriguez, J. M., Karikari, T. K., Blennow, K., Zetterberg, H., Ashton, N. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01685-6 · Cited by 11
Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS Study
Windon, C., Gatsonis, C. A., Carrillo, M. C., Romanoff, J., Hanna, L., Glavin, E. E., Gareen, I. F., Gutman, R., Hillner, B. E., March, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70504 · Cited by 11
Self-citation
Principal-Component Analysis–Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes
Blazhenets, G., Frings, L., Sörensen, A., & Meyer, P. T. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.252783 · Cited by 10
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease
Cai, Y. Q., Fang, L., Yang, J., Zhou, X. Y., Liu, L., Li, A., Sun, P., Lan, G., He, Z., Zhu, Y., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.1801 · Cited by 10
Self-citation
Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy
Zhang, J., Soleimani‐Meigooni, D. N., Koeppe, R. A., Ackley, S. F., Schonhaut, D. R., Lin, Z. E., Maiti, P., Yballa, C., Rocha, S., Shankar, R. P., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270607 · Cited by 9
Self-citation
Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases
Cerman, J., Škorvagová, A., Vyhnálek, M., Veverová, K., Dvořák, K., Kozák, Š., Kavka, A., & Hort, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-23759-5 · Cited by 9
Cardiovascular risk of dementia is associated with brain–behaviour changes in cognitively healthy, middle-aged individuals
Deng, F., Dounavi, M., Plini, E. R. G., Ritchie, K. A., Terrera, G. M., Hutchinson, S., Malhotra, P., Ritchie, C. W., LAWLOR, B. A., & Naçi, L. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.09.006 · Cited by 8
Plasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum
Woo, K. A., Yoon, E. J., Kim, R., Kim, H., Kim, S.-Y., Jin, B., Lee, S., Kim, Y. K., Nam, H., & Lee, J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70788 · Cited by 9
Plasma and neuroimaging biomarkers of small vessel disease and Alzheimer's disease in a diverse cohort: MESA
Lockhart, S. N., Sutphen, C. L., Tanley, J. E., González‐Ortiz, F., Kac, P. R., Habes, M., Heckbert, S. R., Ashton, N. J., Mielke, M. M., Koeppe, R. A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71131 · Cited by 9
Self-citation
Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth
Reinartz, M., Luckett, E. S., Schaeverbeke, J. M., Meyer, S. D., Adamczuk, K., Thal, D. R., Laere, K. V., Dupont, P. J., & Vandenberghe, R. R. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05808-7 · Cited by 8
Preclinical Evaluation of Novel PET Probes for Dementia
Cools, R., Kerkhofs, K., Leitao, R. C. F., & Bormans, G. M. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.03.004 · Cited by 9
Deep Learning-Driven Estimation of Centiloid Scales from Amyloid PET Images with 11C-PiB and 18F-Labeled Tracers in Alzheimer’s Disease
Yamao, T., Miwa, K., Kaneko, Y., Takahashi, N., Miyaji, N., Hasegawa, K., Wagatsuma, K., Kamitaka, Y., Ito, H., & Matsuda, H. (2024) · Brain Sciences · doi:10.3390/brainsci14040406 · Cited by 7
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease
Blazhenets, G., Soleimani‐Meigooni, D. N., Chiotis, K., Allen, I. E., Rabinovici, G. D., Joie, R. L., Meta-Centiloid Study Group, Apostolova, L. G., Asken, B. M., Bejanin, A., et al. (2026) · JAMA · doi:10.1001/jama.2026.13116 · Cited by 11
Self-citation
Comparison and cutoff values of two amyloid PET scaling methods: centiloid scale and amyloid-β load
Yamakuni, R., Abe, M., Ukon, N., Matsuda, H., Takano, H., Sawamoto, N., Shima, A., Mori, Y., Sekino, H., Ishii, S., et al. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02051-6 · Cited by 7

Authors: La Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., Ikonomovic, M. D., Jack, C., Jagust, W. J., Jin, L., Klunk, W. E., Kofler, J., Lesman‐Segev, O. H., Lockhart, S. N., Lowe, V. J., Masters, C. L., Mathis, C. A., McLean, C. L., Miller, B. L., Mungas, D., O'Neil, J. P., Olichney, J. M., Parisi, J. E., Petersen, R. C., Rosen, H. J., Rowe, C. C., Spina, S., Vemuri, P., Villemagne, V. L., Murray, M. E., & Rabinovici, G. D.
Affiliations: Memory & Aging Center Department of Neurology University of California San Francisco CA USA
University of California, San Francisco (US)
Loyola University Chicago (US)
University of California, Davis (US)
Austin Health (AU)
Department of Neurology University of Pittsburgh PA USA
Mayo Clinic (US)
University of California, Berkeley (US)
University of Pittsburgh (US)
Wake Forest University Health Sciences (US)
The University of Melbourne (AU)
The Alfred Hospital (AU)
Helen Wills Neuroscience Institute University of California Berkeley CA USA
ORCID: Ayakta, Nagehan
Seeley, William W.
Boxer, Adam L.
DeCarli, Charles
Doré, Vincent
Grinberg, Lea T.
Huang, Eric
Hwang, Ji‐Hye
Jack, Clifford
Jagust, William J.
Klunk, William E.
Kofler, Julia
Lesman‐Segev, Orit H.
Lockhart, Samuel N.
Lowe, Val J.
Masters, Colin L.
Mathis, Chester A.
McLean, Catriona L.
Miller, Bruce L.
Olichney, John M.
Petersen, Ronald C.
Rosen, Howard J.
Rowe, Christopher C.
Spina, Salvatore
Vemuri, Prashanthi
Villemagne, Victor L.
Murray, Melissa E.
Rabinovici, Gil D.
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2018-10-19
Volume: 15
Issue: 2
Pages: 205-216
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2018.09.001
PMC: PMC6368897
OpenAlex: W2897964327
Cited by: 317
References: 47
Citations by year: 2026: 49 · 2025: 72 · 2024: 51 · 2023: 31 · 2022: 40 · 2021: 42 · 2020: 22 · 2019: 10
FWCI: 14.46
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alzheimer s & Dementia (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: Biogen
Genentech
GE Healthcare
National Institutes of Health
National Institute on Aging
National Cancer Institute
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: Alzheimer's disease, 11C-PiB PET
MeSH terms: Neuropathology, Aged, Alzheimer Disease, Aniline Compounds, Autopsy, Female, Humans, Male, Retrospective Studies, Thiazoles, Positron-Emission Tomography, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks